Specified Treatments for Common Breast Cancer Cases Containing a p53 Mutation Review

With breast cancer being one of the most common causes of death, many researchers have looked into mutations that commonly appear and how they could affect the treatment a patient decides to receive. Mutations in gene TP53 are present in over one third of breast cancer cases, so it is a frequent mutation that is carefully researched and examined. This study aims to review how a mutation in p53 gene in breast cancer patients can influence the form of treatment. Elimination and reviewing of open-source papers, resulted in constant keywords added to the search for specified treatments in modern-day medical technology that have been used or will be in the future. COTI-2 and APR-246 are the compounds that at the time this research was most recently completed, in 2023, have been undergoing clinical trial to be used on patients showing this mutation. Although there have been published papers on this mutation for decades, there is yet to be enough research completed to know whether or not these compounds will positively or negatively impact the process of p53 mutation present treatment plans.